Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160966 | 0.71 | HSD11B1 (0.30) | HSD11B1MAPT | |
| SCHEMBL7594383 | 0.67 | — | — | |
| SCHEMBL6160607 | 0.65 | MEN1 (0.31) | — | |
| SCHEMBL1033155 | 0.65 | ALDH1A1 (0.35) | CYP2C9HSD11B1MAPTTP53GAA | |
| SCHEMBL2747723 | 0.63 | HSD11B1 (0.42) | CYP2C9HSD11B1GAA | |
| SCHEMBL14084250 | 0.63 | MAPT (0.32) | CYP2C9MAPTTP53GAA | |
| SCHEMBL17352397 | 0.61 | ALDH1A1 (0.33) | CYP2C9HSD11B1MAPT | |
| SCHEMBL40305 | 0.61 | ALDH1A1 (0.33) | CYP2C9HSD11B1MAPT | |
| SCHEMBL3813601 | 0.61 | NPSR1 (0.42) | CYP2C9GAA | |
| Adamantane SCHEMBL27604496 | 0.60 | CYP2C9 (0.50) | CYP2C9HSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1496056-B1 | NOVEL COMPOUNDS AND ANTIMALARIALS | UNIV OKAYAMA (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-7407984-B2 | Tetraoxaspriro anti-malarials | OKAYAMA UNIVERSITY (JP) | 2008-08-05 | — | — | US | disclosed |
| WO-2008038030-A2 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2008-04-03 | — | — | WO | disclosed |
| US-20050131058-A1 | Novel compounds and antimalarials | OKAYAMA UNIVERSITY (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1496056-A1 | NOVEL COMPOUNDS AND ANTIMALARIALS | Okayama University (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | NR1H2, NR1H3, NR1I2 | CYP2C9 294/4885HSD11B1 126/4885MAPT 4151/4885 |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | NR1H3, NR1H2, NR1I2 | CYP2C9 293/4885HSD11B1 65/4885MAPT 4354/4885 |
| US-20050131058-A1 | Novel compounds and antimalarials | SQLE, NR1H3, ALOX15 | CYP2C9 392/4885HSD11B1 330/4885MAPT 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.